4.8 Article

Sustained release and protein stabilization reduce the growth factor dosage required for human pluripotent stem cell expansion

Journal

BIOMATERIALS
Volume 248, Issue -, Pages -

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2020.120007

Keywords

Biomaterials; Growth factor delivery; Stem cells; Biomanufacturing; Protein stabilization

Funding

  1. Materials Science Center [NSF DMR-1121288]
  2. UW Carbone Cancer Center Flow Cytometry Laboratory [P30 CA014520]
  3. UW Comparative Pathology Laboratory at UWMadison
  4. National Institutes of Health [R01HL093282]
  5. National Institutes of Health (Biotechnology Training Program) [NIGMS 5 T32-GM08349]
  6. U.S. Environmental Protection Agency (STAR grant) [83573701]
  7. National Science Foundation [DGE-1256259, DMR-1306482]

Ask authors/readers for more resources

Translation of human pluripotent stem cell (hPSC)-derived therapies to the clinic demands scalable, cost-effective methods for cell expansion. Culture media currently used for hPSC expansion rely on high concentrations and frequent supplementation of recombinant growth factors due to their short half-life at physiological temperatures. Here, we developed a biomaterial strategy using mineral-coated microparticles (MCMs) to sustain delivery of basic fibroblast growth factor (bFGF), a thermolabile protein critical for hPSC pluripotency and proliferation. We show that the MCMs stabilize bFGF against thermally induced activity loss and provide more efficient sustained release of active growth factor compared to polymeric carriers commonly used for growth factor delivery. Using a statistically driven optimization approach called Design of Experiments, we generated a bFGF-loaded MCM formulation that supported hPSC expansion over 25 passages without the need for additional bFGF supplementation to the media, resulting in greater than 80% reduction in bFGF usage compared to standard approaches. This materials-based strategy to stabilize and sustain delivery of a thermolabile growth factor has broad potential to reduce costs associated with recombinant protein supplements in scalable biomanufacturing of emerging cell therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available